Study Details
Long-Term Follow-Up of Patients Who Received Lentiviral-Based CAR-T Cell Therapy
(IRB#: IRB_00079262)
People with specific types of cancer such as leukemia and lymphomas may receive Lentiviral-Based CAR-T Cell Therapy. This is to help improve the symptoms of this disease. Research is needed to learn the long-term safety and effectiveness of the therapy. The information we gain may provide further guidance to patients, doctors, and researchers.
- All genders
- Over 7 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 7 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 7 and older
- Received the CD19 CAR T-cell therapy made by Novartis or Penn
- Attend in-person at the University of Utah
Exclusion Criteria
- No specific criteria
Will I be paid for my time?
Yes
IRB#: IRB_00079262
PI: Michael Pulsipher
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2015-06-18 06:00:00
Study Categories: Cancer Studies
Specialties: Pediatric Hematology & Oncology